Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of GSK1557484A H5N1 Vaccine in Adults
NCT01416571Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2011
- Primary completion
- Nov 2011
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted in Influenza A H5N1 infection (H5N1), sponsored by GSK. Started Aug 2011; status: completed.
02
Drugs
Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
03
Conditions
Influenza A H5N1 infection (H5N1)
Beyond the preview
Go deeper on NCT01416571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01416571.